When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

   www.aol.com/fda-approves-biosimilars-macular...

   These drugs are approved to treat neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. View the ...

3. Anti-VEGF - Wikipedia

   en.wikipedia.org/wiki/Anti-VEGF

   A 2014 Cochrane Systematic Review studied the effectiveness of ranibizumab and pegaptanib, on patients who have macular edema caused by central retinal vein occlusion. [5] Participants in both treatment groups showed improvement in visual acuity measures and a reduction in macular edema symptoms over six months. [5]

4. Stem cell therapy for macular degeneration - Wikipedia

   en.wikipedia.org/wiki/Stem_cell_therapy_for...

   Induced pluripotent stem cell taken from blood cell and converted in retinal pigment epithelium. Stem cell therapy for macular degeneration is an emerging treatment approach aimed at restoring vision in individuals suffering from various forms of macular degeneration, particularly age-related macular degeneration (AMD). [1]

5. Cone dystrophy - Wikipedia

   en.wikipedia.org/wiki/Cone_dystrophy

   Cone dystrophy; Fundus of a 45 year-old patient with cone rod dystrophy segregating with a loss-of-function mutation (E1087X) in ABCA4. Note the presence of various-shaped pigment deposits in the posterior pole with atrophy of the retina, while the retina appears less damaged in periphery (upper part of the photograph).

6. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Common adverse effects of the eye formulation include conjunctival hemorrhage, eye pain, cataract, vitreous detachment, floaters, and ocular hypertension. [11]Aflibercept (Zaltrap) has adverse effects typical of anti-cancer drugs, such as reduced blood cell count (leukopenia, neutropenia, thrombocytopenia), gastrointestinal disorders like diarrhea and abdominal pain, and fatigue.

7. Pegcetacoplan - Wikipedia

   en.wikipedia.org/wiki/Pegcetacoplan

   Pegcetacoplan was approved for the treatment of paroxysmal nocturnal haemoglobinuria in the European Union in December 2021. [11] [27] In June 2024, the CHMP recommended the refusal of a marketing authorization for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration.